Medipharm Labs Corp (LABS) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.022x

Based on the latest financial reports, Medipharm Labs Corp (LABS) has a cash flow conversion efficiency ratio of -0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-778.00K ≈ $-562.79K USD) by net assets (CA$35.10 Million ≈ $25.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LABS net asset quality index to measure how much of total assets are equity-financed.

Medipharm Labs Corp - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Medipharm Labs Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Medipharm Labs Corp (LABS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Medipharm Labs Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medipharm Labs Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Flagship Investments Ltd AU:FSI	-0.006x
Egeplast Ege Plastik Ticaret ve Sanayi AS IS:EPLAS	-0.008x
Country Club Hospitality & Holidays Limited NSE:CCHHL	0.014x
Carnavale Resources Ltd AU:CAV	-0.017x
ODTech Co. Ltd KQ:080520	-0.012x
enX Group Ltd JSE:ENX	0.059x
Sebang Co Ltd KO:004365	0.025x
Global Uranium and Enrichment Ltd AU:GUE	-0.029x

Annual Cash Flow Conversion Efficiency for Medipharm Labs Corp (2016–2025)

The table below shows the annual cash flow conversion efficiency of Medipharm Labs Corp from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Medipharm Labs Corp.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CA$35.81 Million ≈ $25.91 Million	CA$-5.50 Million ≈ $-3.98 Million	-0.154x	-36.54%
2024-12-31	CA$43.18 Million ≈ $31.24 Million	CA$-4.86 Million ≈ $-3.52 Million	-0.113x	+51.65%
2023-12-31	CA$53.01 Million ≈ $38.34 Million	CA$-12.34 Million ≈ $-8.93 Million	-0.233x	+18.87%
2022-12-31	CA$56.01 Million ≈ $40.51 Million	CA$-16.07 Million ≈ $-11.62 Million	-0.287x	-80.55%
2021-12-31	CA$83.15 Million ≈ $60.15 Million	CA$-13.21 Million ≈ $-9.56 Million	-0.159x	+67.01%
2020-12-31	CA$78.41 Million ≈ $56.72 Million	CA$-37.77 Million ≈ $-27.32 Million	-0.482x	-150.20%
2019-12-31	CA$131.23 Million ≈ $94.93 Million	CA$-25.27 Million ≈ $-18.28 Million	-0.193x	+51.76%
2018-12-31	CA$27.84 Million ≈ $20.14 Million	CA$-11.11 Million ≈ $-8.04 Million	-0.399x	-410.70%
2017-12-31	CA$-2.12 Million ≈ $-1.54 Million	CA$166.00K ≈ $120.08K	-0.078x	+69.21%
2016-12-31	CA$215.46K ≈ $155.86K	CA$-54.69K ≈ $-39.56K	-0.254x	--

About Medipharm Labs Corp

TO:LABS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$23.05 Million

CA$31.86 Million CAD

Market Cap Rank

#24608 Global

#941 in Canada

Share Price

CA$0.08

Change (1 day)

+0.00%

52-Week Range

CA$0.06 - CA$0.09

All Time High

CA$7.17